In the present study, we found out that the HER2-positive group had a significantly higher rate of visceral and other (than locoregional and bone metastasis) metastasis sites; consistently, in no recurrence/metastasis category, the HER2-positive group was significantly lower than the HER2-negative and HER2-low participants. The gene discussed is ERBB2; the disease is bone metastasis.